Arbutus Biopharma Corp (I9DN)

2.726 +0.050 (+1.87%)
Delayed Data EUR Disclaimer

I9DN Financial Summary

Arbutus Biopharma Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 18.14 million compared to USD 39.02 million a year ago. Net loss was USD 72.85 million compared to USD 69.46 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.44 compared to USD 0.46 a year ago.
TTM
Trailing Twelve Months
MRQ
Most Recent Quarter
I9DN
Gross margin TTM -306.26%
Operating margin TTM -430.15%
Net Profit margin TTM -401.57%
Return on Investment TTM -50.81%
Total Revenue
Net Income
Title
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Total Revenue 2.14 4.66 4.65 6.69
Gross Profit -15.42 -15.51 -13.04 -11.59
Operating Income -20.52 -21.35 -19.02 -17.14
Net Income -19.31 -20.10 -17.09 -16.34
Clear All
0Selected
Please try another search
I9DN
Quick Ratio MRQ 5.68
Current Ratio MRQ 5.87
LT Debt to Equity MRQ 6.56%
Total Debt to Equity MRQ 8.23%
Total Assets
Total Liabilities
Title
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Total Assets 144.40 158.64 176.82 191.22
Total Liabilities 38.38 39.30 42.13 47.31
Total Equity 106.02 119.34 134.69 143.92
Clear All
0Selected
Please try another search
I9DN
Cash Flow/Share TTM -0.51
Revenue/Share TTM 0.11
Operating Cash Flow -76.88%
Cash
Net Change in Cash
Title
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Cash From Operating Activities -17.29 -21.78 -19.56 -27.30
Cash From Investing Activities 22.22 10.43 1.44 16.68
Cash From Financing Activities 3.81 1.68 4.74 20.42
Net Change in Cash 8.75 -9.67 -13.38 9.80
Clear All
0Selected
Please try another search

* In Millions of USD (except for per share items)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.